Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAK study of emtricitabine or lamivudine monotherapy in failing HIV-1 infection
2006-001681-16Phase 2Completed
- Sponsor
- Fondazione Nadir
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emtricitabine and lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Fondazione Nadir. Primary endpoint: Proportion of patients with immunological response over 12 weeks. Started May 2006; status: completed.
02
Drugs
emtricitabinelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-001681-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001681-16.